Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. has good growth characteristics. Rigel Pharmaceuticals, Inc. is not very popular among insiders. Rigel Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and dev...
RIGL Fundamental Data by TradingView

News

Rigel to Present at the 2024 Cantor Global Healthcare Conference
Rigel to Present at the 2024 Cantor Global Healthcare Conference

PR Newswire Rigel to Present at the 2024 Cantor Global Healthcare Conference Rigel to Present at the 2024 Cantor Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 SOUTH SAN...\n more…

Rigel Pharmaceuticals: First patient enrolled in Phase 1b/2 REZLIDHIA trial
Rigel Pharmaceuticals: First patient enrolled in Phase 1b/2 REZLIDHIA trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (olutasidenib) in mIDH1 AML
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (olutasidenib) in mIDH1 AML

PR Newswire Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (olutasidenib) in mIDH1 AML Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of...\n more…

Rigel Expands Relationship with Kissei to include REZLIDHIA (olutasidenib) in Japan, the Republic of Korea and Taiwan
Rigel Expands Relationship with Kissei to include REZLIDHIA (olutasidenib) in Japan, the Republic of Korea and Taiwan

PR Newswire Rigel Expands Relationship with Kissei to include REZLIDHIA (olutasidenib) in Japan, the Republic of Korea and Taiwan Rigel Expands Relationship with Kissei to include REZLIDHIA (olutasidenib) in...\n more…

Rigel Pharmaceuticals (NASDAQ:RIGL) adds US$26m to market cap in the past 7 days, though investors from three years ago are still down 67%
Rigel Pharmaceuticals (NASDAQ:RIGL) adds US$26m to market cap in the past 7 days, though investors from three years ago are still down 67%

Simply Wall St Research Rigel Pharmaceuticals' (Nasdaq:RIGL) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.\n more…

Rigel to Participate in Upcoming September Investor Conferences
Rigel to Participate in Upcoming September Investor Conferences

PR Newswire Rigel to Participate in Upcoming September Investor Conferences Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 SOUTH SAN...\n more…